A novel partial agonist of peroxisome proliferator-activated receptor-γ (PPARγ) recruits PPARγ-coactivator-1α, prevents triglyceride accumulation, and potentiates insulin signaling in vitro

Molecular Endocrinology

Volumn 20, Issue 4, 2006, Pages 809-830

  Burgermeister, Elke ^a   Schnoebelen, Astride ^a   Flament, Angele ^a   Benz, Jörg ^a   Stihle, Martine ^a   Gsell, Bernard ^a   Rufer, Arne ^a   Ruf, Armin ^a   Kuhn, Bernd ^a   Märki, Hans Peter ^a   Mizrahi, Jacques ^a   Sebokova, Elena ^a   Niesor, Eric ^a   Meyer, Markus ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,4 DIMETHOXYBENZYL) 6,7 DIMETHOXY 4 [4 (2 METHOXYPHENYL)PIPERIDIN 1 YLMETHYL]ISOQUINOLINE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; FARGLITAZAR; GLUCOSE; GW 2570; INSULIN; ISOQUINOLINE DERIVATIVE; LIGAND; MESSENGER RNA; PA 082; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN KINASE B; ROSIGLITAZONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOCYTE; AGONIST; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CRYSTAL; DOWN REGULATION; DRUG ANTAGONISM; DRUG SELECTIVITY; ENERGY EXPENDITURE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLUCOSE TRANSPORT; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGAND BINDING; MESENCHYMAL STEM CELL; MOUSE; MOUSE STRAIN; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSACTIVATION; WILD TYPE;

ADIPOCYTES; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; BINDING SITES; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DNA, COMPLEMENTARY; GLUCOSE; HEAT-SHOCK PROTEINS; HUMANS; INSULIN; ISOQUINOLINES; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PPAR GAMMA; PROTEIN CONFORMATION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; MURINAE;

EID: 33645394377     PISSN: 08888809     EISSN: 08888809     Source Type: Journal    
DOI: 10.1210/me.2005-0171     Document Type: Article

References (65)

1. Rosen ED, Spiegelman BM 2001 PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276:37731-37734
2. Ge K, Guermah M, Yuan CX, Ito M, Wallberg AE, Spiegelman BM, Roeder RG 2002 Transcription coactivator TRAP220 is required for PPARγ 2-stimulated adipogenesis. Nature 417:563-567
3. Cock TA, Houten SM, Auwerx J 2004 Peroxisome proliferator-activated receptor-γ: too much of a good thing causes harm. EMBO Rep 5:142-147
4. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R 2004 Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27:256-263
5. Michalik L, Desvergne B, Wahli W 2004 Peroxisomeproliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 4:61-70
6. Rangwala SM, Lazar MA 2002 The dawn of the SPPARMs? Sci STKE 121:PE9
7. Miller AR, Etgen GJ 2003 Novel peroxisome proliferatoractivated receptor ligands for type 2 diabetes and the metabolic syndrome. Expert Opin Investig Drugs 12:1489-1500
8. Smith CL, O'Malley BW 2004 Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25:45-71
9. Picard F, Gehin M, Annicotte J, Rocchi S, Champy MF, O'Malley BW, Chambon P, Auwerx J 2002 SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell 111:931-941
10. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM 1998 A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92:829-839
11. Lin J, Handschin C, Spiegelman BM 2005 Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1:361-370
12. Semple RK, Crowley VC, Sewter CP, Laudes M, Christodoulides C, Considine RV, Vidal-Puig A, O'Rahilly S 2004 Expression of the thermogenic nuclear hormone receptor coactivator PGC-1α is reduced in the adipose tissue of morbidly obese subjects. Int J Obes Relat Metab Disord 28:176-179
13. Guan HP, Ishizuka T, Chui PC, Lehrke M, Lazar MA 2005 Corepressors selectively control the transcriptional activity of PPARγ in adipocytes. Genes Dev 19:453-461
14. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC 2003 PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267-273
15. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, Miyazaki Y, Kohane I, Costello M, Saccone R, Landaker EJ, Goldfine AB, Mun E, DeFronzo R, Finlayson J, Kahn CR, Mandarino LJ 2003 Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 100:8466-8471
16. Hammarstedt A, Jansson PA, Wesslau C, Yang X, Smith U 2003 Reduced expression of PGC-1 and insulin-signaling molecules in adipose tissue is associated with insulin resistance. Biochem Biophys Res Commun 301:578-582
17. Hara K, Tobe K, Okada T, Kadowaki H, Akanuma Y, Ito C, Kimura S, Kadowaki T 2002 A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to type II diabetes. Diabetologia 45:740-743
18. Oberkofler H, Linnemayr V, Weitgasser R, Klein K, Xie M, Iglseder B, Krempler F, Paulweber B, Patsch W 2004 Complex haplotypes of the PGC-1α gene are associated with carbohydrate metabolism and type 2 diabetes. Diabetes 53:1385-1393
19. Lin J, Wu PH, Tarr PT, Lindenberg KS, St-Pierre J, Zhang CY, Mootha VK, Jager S, Vianna CR, Reznick RM, Cui L, Manieri M, Donovan MX, Wu Z, Cooper MP, Fan MC, Rohas LM, Zavacki AM, Cinti S, Shulman GI, Lowell BB, Krainc D, Spiegelman BM 2004 Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1α null mice. Cell 119:121-135
20. Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S, Courtois M, Wozniak DF, Sambandam N, Bernal-Mizrachi C, Chen Z, Holloszy JO, Medeiros DM, Schmidt RE, Saffitz JE, Abel ED, Semenkovich CF, Kelly DP 2005 PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 3:e101
21. Bruderer H, Kierstead RW, Mullin JG, Nakamura K, O'Brien JP, Tateishi M, Teitel S 1984 Substituted isoquinoline derivatives and pharmaceutical compositions containing them. Eur Pat Appl, 62 pp CODEN: EPXXDW EP 126480 A1 19841128 CAN 102:132070 AN 1985:132070 CAPLUS
22. Gampe RT, Montana VG, Lambert MH, Miller AB, Bledsoe RK, Milburn MV, Kliewer SA, Willson TM, Xu HE 2000 Asymmetry in the PPARγ/RXRα crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol Cell 5:545-555
23. Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, Cobb JE, Lenhard JM, Hull-Ryde EA, Mohr CP, Blanchard SG, Parks DJ, Moore LB, Lehmann JM, Plunket K, Miller AB, Milburn MV, Kliewer SA, Willson TM 1999 A peroxisome proliferator-activated receptor γ ligand inhibits adipocyte differentiation. Proc Natl Acad Sci U S A 96:6102-6106
24. Burgermeister E, Tencer L, Liscovitch M 2003 Peroxisome proliferator-activated receptor-γ upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells. Oncogene 22:3888-3900
25. Tang QQ, Otto TC, Lane MD 2004 Commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage. Proc Natl Acad Sci USA 101:9607-9611
26. Gao Z, Zuberi A, Quon MJ, Dong Z, Ye J 2003 Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases. J Biol Chem 278:24944-24950
27. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV 1998 Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395:137-143
28. Ostberg T, Svensson S, Selen G, Uppenberg J, Thor M, Sundbom M, Sydow-Backman M, Gustavsson AL, Jendeberg L 2004 A new class of peroxisome proliferatoractivated receptor agonists with a novel binding epitope shows antidiabetic effects. J Biol Chem 279:41124-41130
29. Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe Jr RT, McKee DD, Moore JT, Willson TM 2001 Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 98:13919-13924
30. Uppenberg J, Svensson C, Jaki M, Bertilsson G, Jendeberg L, Berkenstam A 1998 Crystal structure of the ligand binding domain of the human nuclear receptor PPARγ. J Biol Chem 273:31108-31112
31. Misra P, Chakrabarti R, Vikramadithyan RK, Bolusu G, Juluri S, Hiriyan J, Gershome C, Rajjak A, Kashireddy P, Yu S, Surapureddi S, Qi C, Zhu YJ, Rao MS, Reddy JK, Ramanujam R 2003 PAT5A: a partial agonist of peroxisome proliferator-activated receptor γ is a potent antidiabetic thiazolidinedione yet weakly adipogenic. J Pharmacol Exp Ther 306:763-771
32. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel L, Plunket KD, Shenk JL, Stimmel JB, Therapontos C, Willson TM, Blanchard SG 2002 Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41:6640-6650
33. Wu Y, Chin WW, Wang Y, Burris TP 2003 Ligand and coactivator identity determines the requirement of the charge clamp for coactivation of the peroxisome proliferator-activated receptor γ. J Biol Chem 278:8637-8644
34. Schreiber SN, Emter R, Hock MB, Knutti D, Cardenas J, Podvinec M, Oakeley EJ, Kralli A 2004 The estrogen-related receptor α(ERRα) functions in PPARγ coactivator 1α (PGC-1α)-induced mitochondrial biogenesis. Proc Natl Acad Sci USA 101:6472-6477
35. Kallen J, Schlaeppi JM, Bitsch F, Filipuzzi I, Schilb A, Riou V, Graham A, Strauss A, Geiser M, Fournier B 2004 Evidence for ligand-independent transcriptional activation of the human estrogen-related receptor α (ERRα): crystal structure of ERRα ligand binding domain in complex with peroxisome proliferator-activated receptor coactivator-1α. J Biol Chem 279:49330-49337
36. Burgermeister E, Schnoebelen A, Flament A, Kuhn B, Maerki HP, Blum D, Mizrahi J, Niesor E, Meyer M, A common theme for partial PPARγ-agonists: recruitment of PGC1α, a central regulator of energy expenditure. Proc 3rd International Symposium on PPARs: efficacy and safety, Monte Carlo, Monaco, 2005, p 19
37. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW 2004 Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 43:993-1002
38. Ljung B, Bamberg K, Dahllof B, Kjellstedt A, Oakes ND, Ostling J, Svensson L, Camejo G 2002 AZ 242, a novel PPARα/γ agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J Lipid Res 43:1855-1863
39. Devasthale PV, Chen S, Jeon Y, Qu F, Shao C, Wang W, Zhang H, Cap M, Farrelly D, Golla R, Grover G, Harrity T, Ma Z, Moore L, Ren J, Seethala R, Cheng L, Sleph P, Sun W, Tieman A, Wetterau JR, Doweyko A, Chandrasena G, Chang SY, Humphreys WG, Sasseville VG, Biller SA, Ryono DE, Selan F, Hariharan N, Cheng PT 2005 Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2- (5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl-]glycine [Muraglitazar/BMS- 298585], a novel peroxisome proliferator-activated receptor α/γ dual agonist with efficacious glucose and lipid-lowering activities. J Med Chem 48:2248-2250
40. Murakami K, Tobe K, Ide T, Mochizuki T, Ohashi M, Akanuma Y, Yazaki Y, Kadowaki T 1998 A novel insulin sensitizer acts as a coligand for peroxisome proliferatoractivated receptor-α (PPAR-α) and PPAR-γ: effect of PPAR-α activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes 47:1841-1847
41. Zhang J, Fu M, Cui T, Xiong C, Xu K, Zhong W, Xiao Y, Floyd D, Liang J, Li E, Song Q, Chen YE 2004 Selective disruption of PPARγ 2 impairs the development of adipose tissue and insulin sensitivity. Proc Natl Acad Sci USA 101:10703-10708
42. Rosen ED, Hsu CH, Wang X, Sakai S, Freeman MW, Gonzalez FJ, Spiegelman BM 2002 C/EBPα induces adipogenesis through PPARγ: a unified pathway. Genes Dev 16:22-26
43. Oberkofler H, Esterbauer H, Linnemayr V, Strosberg AD, Krempler F, Patsch W 2002 Peroxisome proliferator-activated receptor (PPAR) γ coactivator-1 recruitment regulates PPAR subtype specificity. J Biol Chem 277:16750-16757
44. Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA 2002 A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 8:1122-1128
45. Haunerland NH, Spener F 2004 Fatty acid-binding proteins - insights from genetic manipulations. Prog Lipid Res 43:328-349
46. Jenkins-Kruchten AE, Bennaars-Eiden A, Ross JR, Shen WJ, Kraemer FB, Bernlohr DA 2003 Fatty acid-binding protein-hormone-sensitive lipase interaction. Fatty acid dependence on binding. J Biol Chem 278:47636-47643
47. Huang H, Starodub O, McIntosh A, Kier AB, Schroeder F 2002 Liver fatty acid-binding protein targets fatty acids to the nucleus. Real time confocal and multiphoton fluorescence imaging in living cells. J Biol Chem 277:29139-29151
48. Jiang G, Dallas-Yang Q, Biswas S, Li Z, Zhang BB 2004 Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor γ (PPARγ), decreases inhibitory serine phosphorylation of IRS1 in vitro and in vivo. Biochem J 377:339-346
49. Peraldi P, Xu M, Spiegelman BM 1997 Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signaling. J Clin Invest 100:1863-1869
50. Standaert ML, Kanoh Y, Sajan MP, Bandyopadhyay G, Farese RV 2002 Cbl, IRS-1, and IRS-2 mediate effects of rosiglitazone on PI3K, PKC-λ, and glucose transport in 3T3/L1 adipocytes. Endocrinology 143:1705-1716
51. Carpentier A, Taghibiglou C, Leung N, Szeto L, Van Iderstine SC, Uffelman KD, Buckingham R, Adeli K, Lewis GF 2002 Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster. J Biol Chem 277:28795-28802
52. Baumann CA, Chokshi N, Saltiel AR, Ribon V 2000 Cloning and characterization of a functional peroxisome proliferator activator receptor-γ-responsive element in the promoter of the CAP gene. J Biol Chem 275:9131-9135
53. Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F, Kitamura Y, Altomonte J, Dong H, Accili D, Spiegelman BM 2003 Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1α interaction. Nature 423:550-555
54. Bhalla S, Ozalp C, Fang S, Xiang L, Kemper JK 2004 Ligand-activated pregnane X receptor interferes with HNF-4 signaling by targeting a common coactivator PGC-1α. Functional implications in hepatic cholesterol and glucose metabolism. J Biol Chem 279:45139-45147
55. Fukui Y, Masui S, Osada S, Umesono K, Motojima K 2000 A new thiazolidinedione, NC-2100, which is a weak PPAR-γ activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes 49:759-767
56. Zhang Y, Castellani LW, Sinal CJ, Gonzalez FJ, Edwards PA 2004 Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev 18:157-169
57. Knutti D, Kressler D, Kralli A 2001 Regulation of the transcriptional coactivator PGC-1 via MAPK-sensitive interaction with a repressor. Proc Natl Acad Sci USA 98:9713-9718
58. Nichols JS, Parks DJ, Consler TG, Blanchard SG 1998 Development of a scintillation proximity assay for peroxisome proliferator-activated receptor γ ligand binding domain. Anal Biochem 257:112-119
59. Zhou G, Cummings R, Hermes J, Moller DE 2001 Use of homogeneous time-resolved fluorescence energy transfer in the measurement of nuclear receptor activation. Methods 25:54-61
60. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA 1995 An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270:12953-12956
61. Tafuri SR 1996 Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes. Endocrinology 137:4706-4712
62. Otwinowski Z, Minor WM 1997 Processing of x-ray diffraction data collected in oscillation mode. Macromolecular crystallography, part A. Methods Enzymol 276:307-326
63. Murshudov GN, Vagin AA, Lebedev A, Wilson KS, Dodson EJ 1999 Efficient anisotropic refinement of macromolecular structures using FFT. Acta Crystallogr D Biol Crystallogr 55:247-255
64. Collaborative Computational Project Number 4 1994 The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50:760-763
65. Gerber PR 1992 Peptide mechanics: a force field for peptides and proteins working with entire residues as smallest units. Biopolymers 32:1003-1017